AstraZeneca's investment in landmark trials in heart failure.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000191:economics; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics; D006801:Humans
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors